Loading…
Zhengye Biotechnology Holding Limited is projected to decline to $0.8083 by 2027, a -7% move from its current price of $0.8667. ZYBT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8253 | $0.8661 | $0.9088 | -0.07% |
| May 30 | $0.8085 | $0.8654 | $0.9265 | -0.14% |
| May 31 | $0.7956 | $0.8648 | $0.9401 | -0.22% |
| Jun 1 | $0.7848 | $0.8642 | $0.9516 | -0.29% |
| Jun 2 | $0.7754 | $0.8636 | $0.9618 | -0.36% |
| Jun 3 | $0.7669 | $0.8629 | $0.971 | -0.43% |
| Jun 4 | $0.7591 | $0.8623 | $0.9795 | -0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7591 | $0.8623 | $0.9795 | -0.51% |
| Week 2 | $0.7165 | $0.8579 | $1.03 | -1.01% |
| Week 3 | $0.6845 | $0.8536 | $1.06 | -1.51% |
| Week 4 | $0.6582 | $0.8493 | $1.10 | -2.01% |
| Week 5 | $0.6355 | $0.845 | $1.12 | -2.51% |
| Week 6 | $0.6153 | $0.8407 | $1.15 | -3.00% |
| Week 7 | $0.597 | $0.8364 | $1.17 | -3.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals.
It exports its products to Vietnam, Pakistan, and Egypt and serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Zhengye Biotechnology Holding Limited (ZYBT) is currently trading at $0.869, with a market cap of $41.18M and a market-rank of 4681. The stock sits in the healthcare sector, focused on veterinary vaccines for livestock and pets in China and related export markets.
The long-term forecast points to a bullish trajectory beyond the near term, with the 2030 avg price at $0.9681 and a 2050 max price of $8.53, suggesting meaningful upside over the next couple of decades. The outlook includes a progression from NEUTRAL to BULLISH sentiment across the forecast horizon, culminating in substantial upside by 2050 (avg $3.71, max $8.53).
A major floor 19.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
The nearest ceiling, 28.1% above — a clean break opens room to run.
A major ceiling 38.5% above — clearing it would confirm fresh momentum.
Key ZYBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZYBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8702 | Sell | $0.8745 | Sell |
| MA 10 | $0.9006 | Sell | $0.8939 | Sell |
| MA 20 | $0.925 | Sell | $0.9144 | Sell |
| MA 50 | $0.9344 | Sell | $0.9507 | Sell |
| MA 100 | $0.941 | Sell | $1.27 | Sell |
| MA 200 | $2.60 | Sell | $2.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.59 | Neutral |
| Stoch RSI (14) | 7.35 | Buy |
| CCI (20) | -85.90 | Neutral |
| Williams %R (14) | -95.33 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -8.74 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 4.67 | Buy |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 25.25 | Buy |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.85 | Buy |
| ADX (14) | 9.09 | Neutral |
| ATR (14) | 0.03 | Info |
Technical sentiment is BEARISH. The RSI(14) sits at 40, with the 50-day simple moving average at $0.9308 and the 200-day simple moving average at $2.64. Support is at $0.867 and resistance at $1.20, framing a narrow near-term window. The 30-day range runs from $0.6201 to $1.22, highlighting notable near-term volatility (annualized volatility 100%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.71 | $0.8667 | $1.21 | 0% | Neutral | |
| $0.5878 | $0.8083 | $1.20 | -7% | Neutral | |
| $0.4801 | $0.6979 | $1.10 | -19% | Bearish | |
| $0.557 | $0.8494 | $1.40 | -2% | Neutral | |
| $0.6163 | $0.9817 | $1.68 | +13% | Neutral | |
| $0.7251 | $1.20 | $2.13 | +39% | Bullish | |
| $0.7513 | $1.30 | $2.36 | +50% | Bullish | |
| $0.6355 | $1.14 | $2.13 | +31% | Bullish | |
| $0.6532 | $1.21 | $2.32 | +40% | Bullish | |
| $0.631 | $1.21 | $2.38 | +40% | Bullish | |
| $0.791 | $1.76 | $3.77 | +103% | Bullish | |
| $1.68 | $3.73 | $8.57 | +330% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.71 | $0.8667 | $1.03 | +0.00% |
| June 2026 | $0.7031 | $0.8413 | $1.04 | -2.93% |
| July 2026 | $0.6672 | $0.8112 | $1.03 | -3.58% |
| August 2026 | $0.6856 | $0.8442 | $1.09 | +4.07% |
| September 2026 | $0.6923 | $0.8613 | $1.13 | +2.03% |
| October 2026 | $0.6626 | $0.8325 | $1.11 | -3.35% |
| November 2026 | $0.6663 | $0.8443 | $1.14 | +1.42% |
| December 2026 | $0.696 | $0.8891 | $1.21 | +5.31% |
Click any year to see its month-by-month ZYBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ZYBT is projected to trade between $0.71 and $1.21, averaging $0.8667 — a potential gain of 0% from today's $0.8667. Price action looks broadly range-bound.
Zhengye Biotechnology Holding Limited's 2027 outlook centres on $0.8083, within a $0.5878 to $1.20 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ZYBT could reach as high as $1.10, with a base case around $0.6979 and support toward $0.4801 — roughly -19% from $0.8667. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect ZYBT to range from $0.557 to $1.40 through 2029. The $0.8494 average target implies a -2% move from current prices. That is up +22% on the projected 2028 average. A consolidation phase looks the most probable path here.
The ZYBT price prediction for 2030 points to an average of $0.9817 (low $0.6163, high $1.68) — a potential gain of +13% on today's $0.8667. Price action looks broadly range-bound.
In 2031, ZYBT is projected to trade between $0.7251 and $2.13, averaging $1.20 — a potential gain of +39% from today's $0.8667. That is up +23% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Zhengye Biotechnology Holding Limited's 2032 outlook centres on $1.30, within a $0.7513 to $2.36 range. That is up +8% on the projected 2031 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2033, ZYBT could reach as high as $2.13, with a base case around $1.14 and support toward $0.6355 — roughly +31% from $0.8667. Buyers look set to stay in control over this stretch.
Expect ZYBT to range from $0.6532 to $2.32 through 2034. The $1.21 average target implies a +40% move from current prices. That is up +7% on the projected 2033 average. Momentum favours further upside here.
The ZYBT price prediction for 2035 points to an average of $1.21 (low $0.631, high $2.38) — a potential gain of +40% on today's $0.8667. Buyers look set to stay in control over this stretch.
In 2040, ZYBT is projected to trade between $0.791 and $3.77, averaging $1.76 — a potential gain of +103% from today's $0.8667. That is up +45% on the projected 2035 average. Momentum favours further upside here.
Zhengye Biotechnology Holding Limited's 2050 outlook centres on $3.73, within a $1.68 to $8.57 range. That is up +112% on the projected 2040 average. That marks a +330% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZYBT today (≈ 1,153.801777 ZYBT) could be worth
$4,299.54
+$3,299.54 (+330%) by 2050 · US Dollar
Based on the average projected ZYBT price of $3.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZYBTwould be worth at today's price.
$1,000 invested in ZYBT on May 27, 2025 (≈ 116.822424 ZYBT) would be worth
$101.25
-$898.75 (-89.9%) today · 0.10× · US Dollar
Based on a ZYBT entry price of $8.56 vs. today's $0.8667.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.888 | $976.01 | -2.4% |
| 1 month ago | $0.881 | $983.77 | -1.6% |
| 3 months ago | $0.81 | $1,070 | +7.0% |
| 6 months ago | $2.09 | $414.69 | -58.5% |
| 1 year ago | $8.56 | $101.25 | -89.9% |
| All time (1.4y) ago | $4.86 | $178.33 | -82.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZYBT forecast.
Our base-case forecast reaches $1.70 around 2040.
Implied market cap at $1.70: $80.57M
The multi-year forecast shows a path from neutral near-term levels toward stronger upside over the longer horizon. For 2026 the min/avg/max are $0.71/$0.869/$1.23 with a 0 ROI and NEUTRAL sentiment. In 2030 the min/avg/max are $0.5913/$0.9681/$1.70 with an 11.4 ROI and NEUTRAL sentiment.
From 2031 onward, forecasts move into bullish territory: 2031 min $0.7026, avg $1.20, max $2.18 (ROI 38.4); 2032 min $0.7247, avg $1.30, max $2.42 (ROI 49); 2033 min $0.5979, avg $1.11, max $2.14 (ROI 28.1); 2034 min $0.6215, avg $1.20, max $2.37 (ROI 38.7); 2035 min $0.592, avg $1.19, max $2.41 (ROI 37.4). The bullish trend strengthens into 2040 (min $0.7857, avg $1.75, max $3.87; ROI 100.9) and culminates in 2050 (min $1.67, avg $3.71, max $8.53; ROI 326.8). These are estimates, not guarantees, and subject to market and company-specific factors.
Tap a question to reveal the answer.
2030 forecast: min $0.5913, avg $0.9681, max $1.70 with ROI 11.4 and sentiment NEUTRAL.
Near term shows mixed signals (2026 NEUTRAL, 2027 NEUTRAL, 2028 BEARISH, 2029 NEUTRAL). From 2031 onward the outlook is BULLISH, with 2031 avg $1.20, 2032 avg $1.30, and by 2050 avg $3.71 with max $8.53 and ROI 326.8, indicating meaningful upside but accompanied by uncertainty.
Yes, the forecast shows price potential beyond $2 in the mid-2020s and early 2030s: 2031 max $2.18; 2032 max $2.42; 2030 max $1.70; and 2050 max $8.53.
Near-term sentiment is BEARISH with 2026 avg $0.869, 2027 $0.7929, 2028 $0.6836, and 2029 $0.8425. The 30-day range is $0.6201 to $1.22, and the stock sits around a support of $0.867 with resistance at $1.20.
Current price is $0.869 and market cap is $41.18M, with a market-rank of 4681.
Zhengye Biotechnology Holding Limited Community Discussion
0Share your Zhengye Biotechnology Holding Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.